NCT00330083已完成1 期
A RANDOMIZED, MULTIPLE DOSE, DOSE-ESCALATION, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE I TRIAL INVESTIGATING THE OPTIMAL SAFE DOSE OF ALK RAGWEED TABLET AMBROSIA ARTEMISIIFOLIA IN ADULT SUBJECTS WITH SEASONAL RHINOCONJUNCTIVITIS CAUSED BY RAGWEED POLLEN ALLERGY
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 72
- 试验地点
- 2
- 主要终点
- Assessment of safety by recording of adverse events
研究概览
简要总结
This trial is performed to assess whether ALK Ragweed Tablet is safe to use in adults
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- Double
入排标准
- 年龄范围
- 18 Years 至 50 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Ragweed pollen induced rhinoconjunctivitis
- •Adults of either sex (18-50 years of age)
- •Positive skin prick test to ragweed
排除标准
- •Previous treatment with immunotherapy
结局指标
主要结局
Assessment of safety by recording of adverse events
次要结局
未报告次要终点
研究者
研究点 (2)
Loading locations...
相似试验
终止
1 期
A Multiple Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AVE8112 in Patients With Parkinson's DiseaseParkinson's DiseaseNCT01803945Michael J. Fox Foundation for Parkinson's Research32
已完成
1 期
Tolerability of ALK Tree TabletAllergyNCT00535639ALK-Abelló A/S
招募中
1 期
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HRS-4729 Injection in Healthy SubjectsOverweight or ObesityNCT06762600Fujian Shengdi Pharmaceutical Co., Ltd.103
已完成
1 期
Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Ascending Doses in HealthyHealthy SubjectsOsteoarthritisNCT00380900Wyeth is now a wholly owned subsidiary of Pfizer
终止
1 期
A Study of ARC-AAT in Healthy Volunteer Subjects and Patients With Alpha-1 Antitrypsin Deficiency (AATD)Alpha-1 Antitrypsin DeficiencyNCT02363946Arrowhead Pharmaceuticals65